All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. The BURN research area collects educational material on compounds that scientists study in the context of energy metabolism, body-composition models, and metabolic signalling. It exists to help laboratory researchers organise and compare reference materials, not to recommend any use in people or animals.
What the BURN research area covers
BURN groups together research compounds that have been examined in published metabolic-science literature. In laboratory and preclinical settings, researchers study how these molecules interact with receptors and pathways tied to appetite signalling, glucose handling, and lipid metabolism. The hub is intended as an organisational starting point: a place to understand what a class of compounds is, what published research has explored, and where each sits in the research pipeline. Nothing in this area should be read as a protocol or as guidance for use outside a controlled laboratory environment.
Kinds of compounds studied here
The compounds catalogued under BURN are predominantly incretin-related peptides and metabolic signalling agents that researchers investigate in metabolic models. Published research has examined single-receptor agonists, dual receptor co-agonists, and triple-receptor agonists that act at combinations of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Studies have examined how these receptor interactions relate to energy expenditure and lipid handling in laboratory systems. Each product page in this area is written in the same research-attributed, educational voice and points back to the underlying literature where available.
- Single-receptor agonist peptides studied in metabolic research.
- Dual receptor co-agonists examined for combined receptor activity.
- Triple-receptor agonists investigated in preclinical and early-phase research.
- Ancillary reference materials used in reconstitution and handling studies.
Research stage and limitations
Many of the compounds discussed here remain investigational. In published research they appear in preclinical models and, for some molecules, in early- and mid-stage clinical research conducted by their originating sponsors. That research is ongoing, and open questions remain around durability of effects, long-term characterisation, and comparative profiles between molecules. Because this material is educational, it does not translate any published finding into a usage instruction. Researchers comparing molecules can use our research finder to navigate the catalogue, and may find the comparative overview of retatrutide, tirzepatide, and semaglutide a useful orientation to how multi-receptor agonists differ.
Handling notes for laboratory work
Research peptides are typically supplied as lyophilised powders that require careful handling, storage, and reconstitution before any in-vitro work. Our general educational walkthrough on how to reconstitute peptides covers good-practice laboratory technique. For deeper background on documentation, storage, and record-keeping, consult the BioRegen research guide. These notes describe laboratory handling only and are not instructions for any use in humans or animals.
Join the BioRegen research list
Get new BURN reference material and catalogue updates by email. New subscribers can use code RESEARCH10 for 10% off a first order.
Selected research references
- Madsbad S, Holst JJ. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opin Investig Drugs. 2025. https://doi.org/10.1080/13543784.2025.2472408
- Abdrabou Abouelmagd A, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2025. https://doi.org/10.1080/08998280.2025.2456441
Reference metadata sourced via PubMed.
All information on this page is provided for laboratory and educational research only. No compound referenced is approved for human or veterinary use, none is intended to diagnose, treat, cure, or prevent any disease, and nothing here constitutes medical advice. BioRegen does not make or endorse claims about outcomes in humans or animals.